TRVI stock forecast, quote, news & analysis

Key Takeaways

• Trevi Therapeutics shares fell roughly 14.2% over the past 30 days, from a closing price of $14.95 on September 18 to about $12.83 in intraday trading on October 20.
• The decline extends a broader pullback, with the stock down roughly 23.5% over the last quarter after a mid-July spike toward $19–$20.
• Negative sector sentiment, including GSK's decision to exit chronic cough development, weighed on the name despite broadly bullish analyst ratings.
• Trevi remains well capitalized with about $319 million in cash and a runway into 2030 as it advances its Phase 3 OCEAN program and Phase 2b LAKE trial for Haduvio.

Trevi Therapeutics (TRVI) Company Overview and Market Position

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine extended-release) as a potential treatment for chronic cough across three indications: idiopathic pulmonary fibrosis (IPF)-related chronic cough, non-IPF interstitial lung disease (ILD)-related chronic cough, and refractory chronic cough (RCC). Haduvio is designed to act on the cough reflex both centrally and peripherally as a kappa agonist and mu antagonist (KAMA), a differentiated mechanism in a category with no FDA-approved therapies.

The company's Phase 2b CORAL trial demonstrated a statistically significant reduction in cough frequency in patients with IPF-related chronic cough, results that were published in JAMA in January 2026. Investors follow the stock closely because of Haduvio's potential to become a first-in-class therapy across large, underserved chronic cough markets and because of the company's multi-year clinical readout calendar.

Trevi Therapeutics (TRVI) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, Trevi Therapeutics declined approximately 14.2%, falling from a $14.95 close on September 18 to about $12.83 in intraday trading on October 20. The move was not a straight line: shares drifted lower through late September and early October, touched the $11.70–$12.00 range in mid-October, and then rebounded modestly in the latest session.

The last quarter tells a similar but larger story. After spiking to roughly $19–$20 in mid-July, shares steadily gave back those gains, closing near $16.77 on July 20 before sliding to the current level of about $12.83, a decline of roughly 23.5% over the period. The broader trend reflects a cooling of near-term momentum even though the stock remains higher on a longer-term basis.

What Drove TRVI Stock Price in the Last 30 Days

Several factors contributed to the 30-day decline. A key pressure point was GSK's decision to halt its chronic cough program and exit the space, which dampened sentiment across the broader chronic cough category. Analysts at Oppenheimer cited the GSK exit as a direct driver of Trevi's recent pullback.

Competitive headlines added to the volatility. Nocion Therapeutics' Phase 2b ASPIRE study of tapulkainium missed its primary endpoint on cough frequency, removing a potential inhaled competitor. While BMO Capital viewed the development as positive for Haduvio's differentiated central-and-peripheral mechanism and reiterated an Outperform rating with a $36 price target, the news also underscored the clinical risk inherent in the chronic cough category.

Company-specific financials were mixed. Second-quarter 2026 results, reported in early August, showed a slightly wider-than-expected loss of $0.11 per share versus a $0.10 consensus. Meanwhile, the company ended the quarter with approximately $319 million in cash, cash equivalents, and marketable securities. Broader risk-off sentiment in small-cap biotech also pressured the shares despite continued bullish analyst coverage.

What Drove TRVI Stock Performance Over the Last Quarter

The quarterly trend has been shaped by an initial catalyst-driven run-up followed by steady give-back. In mid-July, an Investor & Analyst Day detailed Trevi's clinical roadmap and commercial ambitions, including an estimated $6 billion peak sales franchise across its three indications and a cash runway into 2030. The event helped lift shares toward their recent highs.

Since then, enthusiasm has cooled as investors reassessed the risk profile of the late-stage pipeline. The GSK exit from chronic cough, competitive readouts, the modest second-quarter earnings miss, and a rotation away from speculative small-cap biotech names combined to unwind the summer gains. Notably, analyst targets have generally moved higher during this stretch, with firms including Raymond James and BMO Capital maintaining above-market price objectives, underscoring the gap between near-term price action and longer-term Street expectations.

Trending AI Robots

For traders seeking a data-driven approach to volatile small-cap names, Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies. Tickeron offers hundreds of AI trading bots that trade thousands of tickers, but only the top-performing and most relevant bots are featured in this section. These bots vary widely in strategy, timeframe, and performance metrics, allowing users to compare approaches rather than rely on a single model. The page provides a useful starting point for investors who want to observe how algorithmic systems are positioning across the market and to evaluate tools that may complement their own research process.

TRVI Stock Forecast Drivers: What Investors Should Watch Next

The most important near-term catalyst is the sample size re-estimation (SSRE) for the Phase 2b LAKE trial in refractory chronic cough, expected in the fourth quarter of 2026. Investors will also monitor enrollment milestones across the Phase 3 OCEAN program, with the OCEAN-2 12-week trial expected to produce topline data in the second half of 2027 and the 52-week OCEAN-1 trial in the first half of 2028. Additional watch items include the company's planned regulatory discussions for its non-IPF ILD program, any updates on the competitive and regulatory landscape for chronic cough, and ongoing cash runway disclosures. As a clinical-stage company with no commercial revenue, Trevi's share price remains sensitive to clinical, regulatory, and sector-wide sentiment shifts.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations